About Entasis Therapeutics
Entasis Therapeutics is a company based in Waltham (United States) founded in 2015 was acquired by Innoviva in May 2022. Entasis Therapeutics has raised $121.9 million across 5 funding rounds from investors including Astrazeneca, Blackstone and TPG. The company has 40 employees as of December 31, 2022. Entasis Therapeutics offers products and services including GIAPREZA, XERAVA, XACDURO, and ZOLIFLODACIN. Entasis Therapeutics operates in a competitive market with competitors including Paratek Pharma, Spero Therapeutics, Cempra, Bugworks Research and Locus Biosciences, among others.
- Headquarter Waltham, United States
- Employees 40 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Innoviva Specialty Therapeutics
-
Annual Revenue
$7 M (USD)40as on Dec 31, 2019
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$121.9 M (USD)
in 5 rounds
-
Latest Funding Round
$25 M (USD), Post-IPO
Aug 28, 2020
-
Investors
Astrazeneca
& 8 more
-
Employee Count
40
as on Dec 31, 2022
-
Acquired by
Innoviva
(May 23, 2022)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Entasis Therapeutics
Entasis Therapeutics offers a comprehensive portfolio of products and services, including GIAPREZA, XERAVA, XACDURO, and ZOLIFLODACIN.
Treats critical care conditions like low blood pressure.
Fights serious bacterial infections in hospitalized patients.
Addresses infections caused by drug-resistant microorganisms.
Targets uncomplicated gonorrhea infections in clinical development.
People of Entasis Therapeutics
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of Entasis Therapeutics
Entasis Therapeutics has successfully raised a total of $121.9M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $25 million completed in August 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Entasis Therapeutics
Entasis Therapeutics has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Astrazeneca, Blackstone and TPG.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Biotech funding, drug development support, and investment in life sciences.
|
Locked | Locked | Locked | |
|
Fund of funds focused on pre-seed and seed-stage companies
|
Locked | Locked | Locked | |
|
Healthcare sector private equity investments are managed by the firm.
|
Locked | Locked | Locked |
Investor details for Entasis Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Entasis Therapeutics
Investment portfolio details for Entasis Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Entasis Therapeutics
Detailed financials for Entasis Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Entasis Therapeutics Comparisons
Peer comparison for Entasis Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Entasis Therapeutics
Entasis Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Paratek Pharma, Spero Therapeutics, Cempra, Bugworks Research and Locus Biosciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for antimicrobial resistant infections are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for drug-resistant bacterial infections are developed.
|
|
| Locked | Locked | Locked |
Clinical-stage pharmaceutical company focused on developing antibacterials
|
|
| Locked | Locked | Locked |
Drugs for antibiotic-resistant infections and cancer are developed.
|
|
| Locked | Locked | Locked |
Developer of therapeutics for infectious disease and inflammatory indications
|
|
| Locked | Locked | Locked |
Therapies for multi-drug resistant infections are developed using bacteriophages.
|
Detailed competitors of Entasis Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Entasis Therapeutics
Complete news archive for Entasis Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Entasis Therapeutics
Entasis Therapeutics was founded in 2015.
Entasis Therapeutics is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
Entasis Therapeutics is a funded company, having raised a total of $121.9M across 5 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Entasis Therapeutics is 40.
Annual revenue of Entasis Therapeutics is $7M as on Dec 31, 2019.
Entasis Therapeutics was founded in 2015 and is based in Waltham, United States, within the biotechnology sector. Focus is placed on developing small-molecule antibiotics targeting multidrug-resistant Gram-negative infections, such as those caused by Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacteriaceae. A single-dose oral therapy for both susceptible and resistant Neisseria gonorrhoeae is also pursued. The lead candidate, ETX0914, is advanced as an oral antibiotic for uncomplicated gonorrhea treatment.
Entasis Therapeutics's top competitors include Spero Therapeutics, Melinta Therapeutics and Vedanta Biosciences.
Entasis Therapeutics offers GIAPREZA, XERAVA, XACDURO, and ZOLIFLODACIN.
Entasis Therapeutics has 9 investors. Key investors include Astrazeneca, Blackstone, TPG, Innoviva, and Frazier Healthcare Partners.